Literature DB >> 18001110

DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes.

Sanjay Kumar Singh1, Shweta Joshi, Alok Ranjan Singh, Jitendra Kumar Saxena, Daya Shankar Pandey.   

Abstract

Water-soluble piano-stool arene ruthenium complexes based on 1-(4-cyanophenyl)imidazole (CPI) and 4-cyanopyridine (CNPy) with the formulas [(eta6-arene)RuCl2(L)] (L = CPI, eta6-arene = benzene (1), p-cymene (2), hexamethylbenzene (3); L = CNPy, eta6-arene = benzene (4), p-cymene (5), hexamethylbenzene (6)) have been prepared by our earlier methods. The molecular structure of [(eta6-C6Me6)RuCl2(CNPy)] (6) has been determined crystallographically. Analogous rhodium(III) complex [(eta5-C5Me5)RhCl2(CPI)] (7) has also been prepared and characterized. DNA interaction with the arene ruthenium complexes and the rhodium complex has been examined by spectroscopic and gel mobility shift assay; condensation of DNA and B-->Z transition have also been described. Arene ruthenium(II) and EPh3 (E = P, As)-containing arene ruthenium(II) complexes exhibited strong binding behavior, however, rhodium(III) complexes were found to be Topo II inhibitors with an inhibition percentage of 70% (7) and 30% (7a). Furthermore, arene ruthenium complexes containing polypyridyl ligands also act as mild Topo II inhibitors (10%, 3c and 40%, 3d) in contrast to their precursor complexes. Complexes 4-6 also show significant inhibition of beta-hematin/hemozoin formation activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001110     DOI: 10.1021/ic700885m

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  4 in total

1.  A potential rhodium cancer therapy: studies of a cytotoxic organorhodium(I) complex that binds DNA.

Authors:  Jeanette R McConnell; Dimple P Rananaware; Deborah M Ramsey; Kai N Buys; Marcus L Cole; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2013-03-14       Impact factor: 2.823

2.  Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.

Authors:  Jun-Feng Kou; Chen Qian; Jin-Quan Wang; Xiang Chen; Li-Li Wang; Hui Chao; Liang-Nian Ji
Journal:  J Biol Inorg Chem       Date:  2011-08-21       Impact factor: 3.358

3.  Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes.

Authors:  Soledad Betanzos-Lara; Abraha Habtemariam; Guy J Clarkson; Peter J Sadler
Journal:  Eur J Inorg Chem       Date:  2011-06-22       Impact factor: 2.524

4.  p-Cymene Complexes of Ruthenium(II) as Antitumor Agents.

Authors:  María Angeles Pujante-Galián; Sergio A Pérez; Mercedes G Montalbán; Guzmán Carissimi; Marta G Fuster; Gloria Víllora; Gabriel García
Journal:  Molecules       Date:  2020-10-31       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.